KR102580997B1 - 단일세포 인간 만능 줄기세포의 계대 및 수확을 위한 제형 - Google Patents
단일세포 인간 만능 줄기세포의 계대 및 수확을 위한 제형 Download PDFInfo
- Publication number
- KR102580997B1 KR102580997B1 KR1020197023895A KR20197023895A KR102580997B1 KR 102580997 B1 KR102580997 B1 KR 102580997B1 KR 1020197023895 A KR1020197023895 A KR 1020197023895A KR 20197023895 A KR20197023895 A KR 20197023895A KR 102580997 B1 KR102580997 B1 KR 102580997B1
- Authority
- KR
- South Korea
- Prior art keywords
- stem cells
- formulation
- cell
- cells
- hpscs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 239
- 238000009472 formulation Methods 0.000 title claims abstract description 236
- 238000003306 harvesting Methods 0.000 title claims abstract description 82
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims abstract description 63
- 210000004027 cell Anatomy 0.000 claims abstract description 267
- 210000000130 stem cell Anatomy 0.000 claims abstract description 74
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 claims abstract description 30
- 239000001509 sodium citrate Substances 0.000 claims abstract description 26
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 25
- 238000007667 floating Methods 0.000 claims abstract description 20
- 239000001103 potassium chloride Substances 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000011780 sodium chloride Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 108
- 239000001963 growth medium Substances 0.000 claims description 58
- 238000004113 cell culture Methods 0.000 claims description 43
- 239000002609 medium Substances 0.000 claims description 34
- 230000004069 differentiation Effects 0.000 claims description 17
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 13
- 230000003833 cell viability Effects 0.000 claims description 11
- 238000005119 centrifugation Methods 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 11
- 238000005516 engineering process Methods 0.000 claims description 9
- 238000005138 cryopreservation Methods 0.000 claims description 8
- 238000011143 downstream manufacturing Methods 0.000 claims description 8
- 210000000604 fetal stem cell Anatomy 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000007747 plating Methods 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 210000002514 epidermal stem cell Anatomy 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 3
- 210000001178 neural stem cell Anatomy 0.000 claims description 3
- 210000001988 somatic stem cell Anatomy 0.000 claims description 3
- 230000001464 adherent effect Effects 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 69
- 239000000243 solution Substances 0.000 description 44
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 29
- 239000000758 substrate Substances 0.000 description 23
- 230000004083 survival effect Effects 0.000 description 23
- 238000004114 suspension culture Methods 0.000 description 21
- 239000011575 calcium Substances 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 18
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 16
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 16
- 238000007790 scraping Methods 0.000 description 15
- 235000011164 potassium chloride Nutrition 0.000 description 14
- 230000002255 enzymatic effect Effects 0.000 description 12
- 239000002738 chelating agent Substances 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 101710144033 Pancreas/duodenum homeobox protein 1 Proteins 0.000 description 10
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 10
- 230000010261 cell growth Effects 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 102100028096 Homeobox protein Nkx-6.2 Human genes 0.000 description 9
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 description 9
- 101000578258 Homo sapiens Homeobox protein Nkx-6.2 Proteins 0.000 description 9
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 9
- 210000001900 endoderm Anatomy 0.000 description 9
- 102000000905 Cadherin Human genes 0.000 description 8
- 108050007957 Cadherin Proteins 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 108010085895 Laminin Proteins 0.000 description 7
- 239000006143 cell culture medium Substances 0.000 description 7
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 108060005980 Collagenase Proteins 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 6
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 6
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 6
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 6
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 108010007093 dispase Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102100035140 Vitronectin Human genes 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 108010076089 accutase Proteins 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 208000037068 Abnormal Karyotype Diseases 0.000 description 3
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 3
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 3
- -1 NANOG Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108010031318 Vitronectin Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 230000006862 enzymatic digestion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 102000014736 Notch Human genes 0.000 description 2
- 108010070047 Notch Receptors Proteins 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 235000021403 cultural food Nutrition 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010079 rubber tapping Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013520 translational research Methods 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000012604 3D cell culture Methods 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008709 cellular rearrangement Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000010372 cloning stem cell Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 238000012789 harvest method Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000003209 hepatic oval cell Anatomy 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000011173 large scale experimental method Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical class [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447262P | 2017-01-17 | 2017-01-17 | |
| US62/447,262 | 2017-01-17 | ||
| PCT/US2018/014032 WO2018136500A1 (en) | 2017-01-17 | 2018-01-17 | Passaging and harvesting formulation for single-cell human pluripotent stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190104407A KR20190104407A (ko) | 2019-09-09 |
| KR102580997B1 true KR102580997B1 (ko) | 2023-09-21 |
Family
ID=61163807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197023895A Active KR102580997B1 (ko) | 2017-01-17 | 2018-01-17 | 단일세포 인간 만능 줄기세포의 계대 및 수확을 위한 제형 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190359946A1 (enExample) |
| EP (1) | EP3555264A1 (enExample) |
| JP (1) | JP7092309B2 (enExample) |
| KR (1) | KR102580997B1 (enExample) |
| CN (1) | CN110291189A (enExample) |
| CA (1) | CA3050259A1 (enExample) |
| IL (1) | IL267628B2 (enExample) |
| WO (1) | WO2018136500A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230059873A1 (en) * | 2019-12-11 | 2023-02-23 | Repairon Gmbh | Expansion of stem cells in suspension in a bioreactor |
| CN114807018B (zh) * | 2022-02-28 | 2023-08-01 | 深圳市旷逸生物科技有限公司 | 一种多能干细胞的传代方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012158899A1 (en) * | 2011-05-17 | 2012-11-22 | Lonza Walkersville Inc. | Passaging and harvesting formulation and method for human pluripotent stem cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2777552C (en) * | 2009-10-19 | 2019-05-21 | Cellular Dynamics International, Inc. | Cardiomyocyte production |
| US9487752B2 (en) * | 2011-03-30 | 2016-11-08 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
| ES2939807T3 (es) * | 2014-03-21 | 2023-04-27 | Fujifilm Cellular Dynamics Inc | Producción de neuronas dopaminérgicas del mesencéfalo y métodos para su utilización |
-
2018
- 2018-01-17 CN CN201880007148.4A patent/CN110291189A/zh active Pending
- 2018-01-17 JP JP2019535360A patent/JP7092309B2/ja active Active
- 2018-01-17 IL IL267628A patent/IL267628B2/en unknown
- 2018-01-17 EP EP18703413.7A patent/EP3555264A1/en active Pending
- 2018-01-17 WO PCT/US2018/014032 patent/WO2018136500A1/en not_active Ceased
- 2018-01-17 CA CA3050259A patent/CA3050259A1/en active Pending
- 2018-01-17 KR KR1020197023895A patent/KR102580997B1/ko active Active
- 2018-07-17 US US16/478,461 patent/US20190359946A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012158899A1 (en) * | 2011-05-17 | 2012-11-22 | Lonza Walkersville Inc. | Passaging and harvesting formulation and method for human pluripotent stem cells |
Also Published As
| Publication number | Publication date |
|---|---|
| IL267628B2 (en) | 2025-06-01 |
| KR20190104407A (ko) | 2019-09-09 |
| JP2020513765A (ja) | 2020-05-21 |
| IL267628B1 (en) | 2025-02-01 |
| US20190359946A1 (en) | 2019-11-28 |
| EP3555264A1 (en) | 2019-10-23 |
| CN110291189A (zh) | 2019-09-27 |
| IL267628A (en) | 2019-08-29 |
| WO2018136500A1 (en) | 2018-07-26 |
| CA3050259A1 (en) | 2018-07-26 |
| JP7092309B2 (ja) | 2022-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zweigerdt | Large scale production of stem cells and their derivatives | |
| Sarvi et al. | Cardiogenesis of embryonic stem cells with liquid marble micro‐bioreactor | |
| Chen et al. | Application of human mesenchymal and pluripotent stem cell microcarrier cultures in cellular therapy: achievements and future direction | |
| Graham et al. | Isolation of mesenchymal stem cells from amniotic fluid and placenta | |
| Cuesta-Gomez et al. | Suspension culture improves iPSC expansion and pluripotency phenotype | |
| US10487312B2 (en) | Passaging and harvesting formulation and method for human pluripotent stem cells | |
| Badenes et al. | Long‐term expansion of human induced pluripotent stem cells in a microcarrier‐based dynamic system | |
| Inamdar et al. | Derivation and characterization of two sibling human embryonic stem cell lines from discarded grade III embryos | |
| KR102580997B1 (ko) | 단일세포 인간 만능 줄기세포의 계대 및 수확을 위한 제형 | |
| Chen et al. | Expansion of human embryonic stem cells on cellulose microcarriers | |
| US10542743B2 (en) | Isolation, expansion and characterization of wharton's jelly mesenchymal stem cells | |
| WO2015008275A1 (en) | Methods for large scale generation of stem cells | |
| Yamada et al. | Using piggyBac transposon gene expression vectors to transfect Zscan5b gene into mouse pluripotent stem cells | |
| Rungarunlert et al. | Novel bioreactor platform for scalable cardiomyogenic differentiation from pluripotent stem cell-derived embryoid bodies | |
| Nakashima et al. | Development of a cell therapy set prototype for autologous iPS cells | |
| Fiacco et al. | Optimized and Scalable Precoating‐Free Reprogramming of Human Peripheral Blood Mononuclear Cells into iPSCs | |
| Olenic et al. | The international journal of animal biosciences | |
| Ribeiro | Cardiac differentiation of human induced Pluripotent Stem Cells in Vertical-Wheel bioreactors | |
| Oh et al. | Advances and perspectives in human and mouse embryonic stem cell bioprocessing | |
| Brena | Characterization of Human Embryonic Stem Cells | |
| Lipsitz | Cell Engineering to Overcome Bottlenecks in Human Pluripotent Stem Cell Based Therapeutic Manufacturing | |
| Trivedi | Enhanced Expansion of Human Pluripotent Stem Cells and Somatic Cell Reprogramming Using Defined and Xeno-Free Culture Conditions | |
| Pekkanen-Mattila | Cardiomyocyte Differentiation from Human Pluripotent Stem Cells | |
| Miettinen | Influence of pluripotent stem cell culture conditions on cardiac differentiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190814 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210115 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20221123 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230623 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20230918 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20230919 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |